Harvard Released a Free Aging Clock. The Longevity Industry Has a Problem With It.
Harvard's longevity lab released a free calculator that measures biological age from a blood or tissue sample. The tool, called TACO (Transcriptomic Age Calculator Online), reads gene activity data — which genes are switched on or off in a given tissue — and outputs a single number: your transcriptomic age, a biological age estimate based on the patterns most consistent with aging across species. The lab made it publicly available at app.gladyshevlab.org/TACO/ with no paywall and no signup requirement. Any researcher can upload a dataset and get a comparable number. That is the novelty — and, for an industry built on biological age claims, the problem.
The longevity industry has turned biological age into a premium product. Supplement companies including Elysium Health and Life Length sell biological age panels alongside their NAD+ precursors and senolytic formulations. Regenerative clinics charge thousands for blood panels that claim to measure how fast someone's cells are aging. The pitch works partly because the underlying tests were opaque: each lab ran its own algorithm, on its own tissue sample, and returned a number nobody else could reproduce. Harvard's TACO, described in a paper published in Nature, is the first biological age clock built on gene activity that the authors released as a free, public web tool — meaning the calculation is reproducible by anyone with RNA data.
Cholesterol offers a rough historical template for what a biological age number can change. Before the 1960s, high cholesterol was treated as an inevitable feature of aging — something to accept rather than target. The Framingham Heart Study began publishing its findings in the 1960s, and once a number existed that was both measurable and modifiable through diet and drugs, the entire medical response to cardiovascular disease shifted. Doctors had a target. Patients had a number to track. The drug industry had a proxy endpoint for clinical trials. The same shift is technically possible with biological age — if the measurement is reproducible and independent labs can run the same test, the number becomes a trial endpoint, a product claim checker, and a clinical decision tool rather than a marketing prop.
The research behind TACO is broad. The team analyzed more than 11,000 transcriptomes — the full set of gene activity readouts in a tissue — from more than 25 tissues across four mammalian species: mice, rats, crab-eating macaques, and humans, according to Nature. Aging consistently turned on genes involved in inflammation, cellular energy dysfunction, and senescence — the process by which cells stop dividing and secrete inflammatory signals. Many of these signatures appeared across organs and species, which the authors argue is why the clock works across tissues and mammals. Two biomarkers in particular, CDKN1A and LGALS3, had protein levels associated with mortality and multimorbidity in the UK Biobank, a large-scale UK health dataset, making them the best-supported links between the clock and real health outcomes, according to Nature. The cross-species universality means a researcher studying a mouse liver dataset can compare their results directly to human tissue data — the same clock, the same units, without requiring a proprietary conversion factor.
Gene activity signatures are more interpretable than the chemical tags studied by older epigenetic clocks because they reflect changes in specific genes rather than an aggregate chemical signal, João Pedro de Magalhães, a gerontology researcher at the University of Birmingham, wrote in an accompanying News & Views article in Nature News & Views. Epigenetic clocks, which measure chemical modifications to DNA, have been the dominant technology for biological age estimation for a decade, but de Magalhães argued their signals are harder to trace back to specific biological processes.
The clock responded to known anti-aging interventions, providing the kind of validation the longevity industry typically asks for without providing. When aging rodents received blood from young donors — a procedure called parabiosis — the transcriptomic age of their tissues shifted measurably, Singularity Hub reported. The effect was consistent with real biological change rather than noise, the authors argued. In humans, the clocks accurately predicted lifespans of participants enrolled in a large heart health study and were sensitive to environmental factors including radiation exposure and chronic diseases, according to Singularity Hub.
To see what accountability looks like in practice: consider a popular senolytic supplement that claims to reduce biological age by three years. Under TACO, an independent researcher could run the supplement on a controlled group, upload the RNA data to the TACO web tool, and report whether the transcriptomic age shift was statistically meaningful and larger than the measurement noise — which is something current proprietary tests cannot be cross-checked against. The claim either survives a reproducible readout or it does not.
TACO is not ready for clinical use. The authors are explicit that transcriptomes shift with stress, illness, and exercise — they are more dynamic than DNA methylation patterns, which makes them harder to interpret as pure age markers. The clock measures cumulative damage burden, not necessarily the cause of aging. Cross-species universality is asserted by the authors and supported by the tissue and species diversity in the dataset, but it has not yet been independently replicated by other labs. The authors themselves note the clock is a research tool, not a diagnostic.
The pressure point is the longevity industry. Supplement companies, testing services, and regenerative clinics have sold biological age as a proxy for intervention efficacy — proof that their product did something measurable. If TACO becomes widely used, independent researchers can run the same datasets and report whether any given supplement, diet, or clinic protocol produced a statistically meaningful shift in transcriptomic age in properly controlled studies. That is a form of accountability the industry has largely avoided. Scientific American covered universal aging clocks as a broader trend in the field.
What to watch next is whether the independent replications arrive — and whether any commercially promoted intervention shows a signal against TACO in a properly controlled trial. The tool is open. The experiment is now reproducible. Whether anyone in the industry wants to run it is a different question.